Isolation of farnesyltransferase inhibitors from herbal medicines

Annals of the New York Academy of Sciences

Volumn 886, Issue , 1999, Pages 261-264

  Kwon, Byoung Mog ^a   Lee, Seung Ho ^a   Kim, Mi Jeong ^a   Kim, Hyae Kyeong ^a   Kim, Hwan Mook ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYCINNAMALDEHYDE; ARTEMINOLIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RHOMBENONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; BODY WEIGHT; CARBON NUCLEAR MAGNETIC RESONANCE; COLON ADENOCARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ISOLATION; DRUG STRUCTURE; HERBAL MEDICINE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR VOLUME;

ANIMALIA;

EID: 0033452553     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb09431.x     Document Type: Conference Paper

References (6)

1. 1. Gibbs, J.B. et al. 1994. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77: 175-178.
2. 2. Qian, Y. et al. 1998. Farnesyltransferase as a target for anticancer drug design. Biopoly. 43: 25-41.
3. 3. Webb, C.P. et al. 1998. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc. Natl. Acad. Sci. USA 95: 8773-8778.
4. 4. Arbiser, J.L. 1997. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA 94: 861-866.
5. 5. Picman, A.K. 1986. Biological activities of sesquiterpene lactones. Biochem. System. Ecol. 14: 255-281.
6. 6. Sebti, S.M. & A.D. Hamilton. 1998. New approaches to anticancer drug design based on the inhibition of farnesyltransferase.DDT 3: 26-33.